Topic: infectious disease
Norovirus and rotavirus get transmitted to humans through "virus clusters" that exacerbate the spread of the illnesses.
GlaxoSmithKline is close to ending a six-decade drought in relapse-preventing therapies for Plasmodium vivax—one of the most common forms of malaria.
New HIV treatments could target a molecule called IP6 to render the virus vulnerable to the immune system.
Novartis is the latest big pharma player to decide that developing new anti-infectives isn’t on its priority list.
Otsuka plans to acquire Visterra and its antibody engineering platform for $430 million in cash, as it aims to build out its discovery efforts.
Scynexis’ antifungal SCY-078 bests the current standard therapy for yeast infections in a midstage trial and is moving to a phase 3 program.
The agreement sees Sanofi transfer 100 employees, more than 10 drug candidates and €60 million upfront to the German service provider.
Vical has yet another drug flop to contend with, giving up on its genital herpes vaccine after earlier failures for CMV and cancer immunotherapies.
Brii Biosciences' mission is to overcome the challenges that have prevented the spread of innovative medicines throughout China.
Genentech and Lodo Therapeutics signed a drug discovery collaboration worth nearly $1 billion, focused on deriving products from DNA found in soil.